The KIT/PDGFRA Inhibitor Ripretinib Shows Signs of Activity in GIST.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2020-124
Abstract: The overall response rate was 19.4% in patients who received ripretinib as a second-line therapy. read more here.
Keywords: signs activity; ripretinib shows; shows signs; inhibitor ripretinib ... See more keywords